awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q51098678-247E617D-08BD-4D6F-A174-D9D5A07AECF6
Q51098678-247E617D-08BD-4D6F-A174-D9D5A07AECF6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51098678-247E617D-08BD-4D6F-A174-D9D5A07AECF6
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M
P2860
Q51098678-247E617D-08BD-4D6F-A174-D9D5A07AECF6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51098678-247E617D-08BD-4D6F-A174-D9D5A07AECF6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e2dbfa10823fc2277cce3c49310341b71399a731
P2860
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome